Resources

Bill, law and research tracker

27 bills, 66 state laws and 18 research papers. This page refreshes itself every minute.

Last refreshed 1:32 PM

Bills (27)

Michigan · 2026 · introducedHB 6020: Participation in ibogaine clinical trialsOfficial bill
Louisiana · 2026 · enactedSB 43: Provides relative to psychedelic-assisted therapyOfficial bill
Pennsylvania · 2026 · introducedSB1149: Pharmaceutical synthetic psilocybin scheduling proposalOfficial bill
Pennsylvania · 2025 · introducedHB1439: FDA-linked psilocybin access proposalOfficial bill
New Mexico · 2025 · enactedSB 219: Medical Psilocybin ActOfficial bill
New York · 2025 · introducedA2142A / S5303A: Allows growth, cultivation and adult use of psilocybin for certain health conditionsOfficial bill
New York · 2025 · introducedA628: Natural hallucinogen adult-use proposalOfficial bill
Arizona · 2025 · introducedHB 2871: Appropriation; ibogaine; clinical research studyOfficial bill
Illinois · 2025 · introducedHB 1143: Compassionate Use and Research of Entheogens ActOfficial bill
Illinois · 2025 · introducedSB 2184: Compassionate Use and Research of Entheogens ActOfficial bill
New Jersey · 2025 · enactedS 2283: Pilot program for psilocybin research; makes an appropriationOfficial bill
Washington · 2025 · introducedHB 1433: Concerning access to psychedelic substancesOfficial bill
Washington · 2025 · introducedSB 5201: Concerning access to psychedelic substancesOfficial bill
Maine · 2025 · failedLD 1034: An Act to Decriminalize Personal Possession of Therapeutic Amounts of Psilocybin for AdultsOfficial bill
California · 2025 · enactedAB 1103: Controlled substances: researchOfficial bill
Michigan · 2025 · introducedHB 4686: Allow psilocybin or psilocin under certain circumstancesOfficial bill
Texas · 2025 · enactedSB 2308: Establishment of a consortium to conduct a clinical trial of ibogaine treatmentOfficial bill
Utah · 2024 · enactedHB 167: Mental illness psychotherapy drug pilotOfficial bill
Vermont · 2024 · enactedS.114: An act relating to the establishment of the Psychedelic Therapy Advisory Working GroupOfficial bill
Maryland · 2024 · enactedSB 1009 / HB 548: Task Force on Responsible Use of Natural Psychedelic SubstancesOfficial bill
Massachusetts · 2024 · failedQuestion 4: Natural psychedelic substances ballot measureOfficial bill
California · 2023 · vetoedSB 58: Decriminalize certain natural psychedelicsOfficial bill
Minnesota · 2023 · enactedHF 100: Psychedelic Medicine Task ForceOfficial bill
Colorado · 2023 · enactedProposition 122 / SB23-290: Natural Medicine Health Act and implementing lawOfficial bill
Washington · 2023 · enactedSB 5263: Psilocybin task force and pilotOfficial bill
Texas · 2021 · enactedHB 1802: Psilocybin treatment research study for veteransOfficial bill
Oregon · 2020 · enactedMeasure 109: Oregon Psilocybin Services ActOfficial bill

State laws (66)

Research papers (18)

Bogenschutz et al. (2022) Psilocybin-assisted psychotherapy vs placebo for alcohol use disorderJAMA Psychiatry
Carhart-Harris et al. (2021) Trial of psilocybin versus escitalopram for depressionNew England Journal of Medicine
Davis et al. (2018) The epidemiology of 5-MeO-DMT use: benefits, consequences, patterns of useJournal of Psychopharmacology
Davis et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorderJAMA Psychiatry
Feifel et al. (2026) Phase 2b randomized trial of intranasal mebufotenin (BPL-003) in treatment-resistant depressionJAMA
Goodwin et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depressionNew England Journal of Medicine
Griffiths et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancerJournal of Psychopharmacology
Human hallucinogen research: guidelines for safety (Johnson, Richards & Griffiths, 2008)Journal of Psychopharmacology
Johnson et al. (2014) Pilot study of psilocybin in the treatment of tobacco addictionJournal of Psychopharmacology
Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Cherian et al., 2024)Nature Medicine
Mitchell et al. (2021) MDMA-assisted therapy for severe PTSDNature Medicine
Mitchell et al. (2023) MDMA-assisted therapy for moderate to severe PTSD: a phase 3 trialNature Medicine
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (Carhart-Harris et al., 2012)PNAS
Ot'alora G et al. (2018) MDMA-assisted psychotherapy for chronic PTSD: a randomized phase 2 trialJournal of Psychopharmacology
Psychedelic harm reduction and integration: a transtheoretical model for clinical practice (Gorman et al., 2021)Frontiers in Psychology
Raison et al. (2023) Single-dose psilocybin treatment for major depressive disorderJAMA
Reckweg et al. (2023) Phase 1/2 trial of vaporized 5-MeO-DMT (GH001) in treatment-resistant depressionFrontiers in Psychiatry
Ross et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancerJournal of Psychopharmacology